Lloyd's Canopius faces downgrade due to sale
Syndicate Research Limited (SRL) has placed Lloyd's syndicate 4444 (Canopius Managing Agents Limited) under review for possible downgrade after confirmation that Sompo Canopius is due to be acquired by a private equity consortium led by Centerbridge Partners in the first quarter of 2018.
Sompo Japan Nipponkoa Insurance is in the process of selling Sompo Canopius for $952 million.
Syndicate 4444’s B+^ (Above Average) Continuity Opinion is likely to be downgraded to B^ (Average) with stable outlook should the sale proceed as planned.
Syndicate 4444 recorded a profit of 1 percent of net premium earned (NPE) on an annually accounted basis for 2016 on a combined ratio of 100 percent (including forex). SRL stated that, in terms of reported results, on a cross-cycle basis, syndicate 4444 had recorded average profits of 6 percent of NPE for 2008 to 2016 under annual accounting.
SRL commented that syndicate 4444’s B+^ (Above Average) Continuity Opinion currently reflected the benefit of group support from Sompo, with the syndicate’s Continuity Opinion considered to be in the B+ peer group after consideration of group support.
However, with a management buy-out and with syndicate 4444’s indicative average returns on capital on a cross-cycle basis in line with the B (Average) peer group on a stand-alone basis, SRL believes that the syndicate’s Continuity Opinion is likely to be better positioned at the top of the B (Average) peer group should the operation be sold by the group as planned.
Get the latest re/insurance news sent to your inbox every day - Sign up to our free email newsletters
Today’s news stories
Swiss Life under US Department of Justice investigation over tax evasion role
Markel underwriting director to step down from top executive role
AmTrust sells management policy system for $200m
AIG places Shariah-compliant insurance policy
Canada Life strikes £1.7bn longevity risk reinsurance agreement
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Elliot Field at efield@newtonmedia.co.uk or Adrian Tapping at atapping@newtonmedia.co.uk
Editor's picks
Editor's picks
More articles
Copyright © intelligentinsurer.com 2024 | Headless Content Management with Blaze